HAM
CRSP icon

Hedges Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Hedges Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
+24,575
New +$1.3M 0.88% 35
2025
Q4 		$1.19M Buy
22,775
+275
+1% +$16.5K 0.84% 43
2025
Q3 		$1.46M Sell
22,500
-2,200
-9% -$126K 1.12% 29
2025
Q2 		$1.2M Sell
24,700
-4,650
-16% -$180K 0.97% 36
2025
Q1 		$999K Buy
29,350
+5,000
+21% +$212K 0.66% 56
2024
Q4 		$958K Buy
24,350
+1,200
+5% +$56.7K 0.63% 55
2024
Q3 		$1.09M Buy
23,150
+1,350
+6% +$68.5K 0.72% 49
2024
Q2 		$1.18M Buy
21,800
+2,425
+13% +$140K 0.85% 42
2024
Q1 		$1.32M Sell
19,375
-2,000
-9% -$143K 0.93% 39
2023
Q4 		$1.34M Sell
21,375
-1,150
-5% -$63.6K 1.05% 33
2023
Q3 		$1.02M Buy
22,525
+3,575
+19% +$185K 0.89% 37
2023
Q2 		$1.06M Buy
18,950
+2,650
+16% +$150K 0.9% 37
2023
Q1 		$737K Buy
16,300
+625
+4% +$30.4K 0.63% 48
2022
Q4 		$637K Buy
15,675
+5,200
+50% +$276K 0.57% 47
2022
Q3 		$685K Sell
10,475
-1,900
-15% -$138K 0.68% 46
2022
Q2 		$753K Buy
12,375
+2,600
+27% +$153K 0.71% 43
2022
Q1 		$614K Buy
9,775
+1,425
+17% +$89.5K 0.48% 61
2021
Q4 		$633K Buy
+8,350
New +$729K 0.49% 60

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hedges Asset Management's CRSP Position: Q2 2026 in Review

Hedges Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 24,575 shares worth $1.34M. The stake represents 0.88% of the portfolio and ranks #35 among its holdings. This is a return to the name: Hedges Asset Management previously reported a position in CRSP as recently as Q4 2025.

Hedges Asset Management first reported a position in CRSP in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.46M in Q3 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Hedges Asset Management held 24,575 shares of CRISPR Therapeutics worth $1.34M as of Q2 2026.
  • CRISPR Therapeutics was a new Hedges Asset Management position in Q2 2026.
  • CRISPR Therapeutics made up 0.88% of Hedges Asset Management's portfolio in Q2 2026, its #35 holding.
  • Hedges Asset Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Hedges Asset Management's CRISPR Therapeutics position peaked at $1.46M in Q3 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Hedges Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.